Effect of Vitamin D and Calcium on Bone in Pediatric HIV

维生素 D 和钙对 HIV 儿童骨骼的影响

• 批准号: 6798704
• 负责人: Stephen M Arpadi
• 金额: $ 50.64万
• 依托单位: ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2007-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6798704
• 关键词: 1,25 dihydroxycholecalciferol; AIDS therapy; HIV infections; adolescence (12-20); antiAIDS agent; antiviral agents; bone density; child (0-11); clinical research; clinical trials; dietary calcium; dietary supplements; drug adverse effect; human subject; interleukin 1; longitudinal human study; medical complication; normal ossification; nutrition related tag; outcomes research; pediatric AIDS; tumor necrosis factor alpha; vitamin D; vitamin deficiency; vitamin therapy

DESCRIPTION (provided by applicant): We have recently observed that HIV-infected children, living in an urban setting in the northeastern United States, have decreased bone mass compared to healthy children. As childhood and adolescence are the critical periods during life for skeletal development and, as it is widely recognized that optimal bone mass accretion during childhood and adolescence may prevent osteoporosis later in life, this observation has serious implications for future risk of osteoporosis and fractures in HIV-infected children. While Highly Active Antiretroviral Treatment (HAART) has been implicated in the etiology of the skeletal demineralization in adults, it remains possible that other factors important for skeletal health, such as vitamin D deficiency, could contribute to or exacerbate bone loss in HIV-infected children. In this regard, we have found that 50% of a small group of HIV-infected children have deficient or insufficient body stores of vitamin D, as measured by serum 25-hydroxyvitamin D levels below 20 ng/ml. The central hypotheses of this proposal are that the prevalence of vitamin D deficiency and insufficiency is increased in HIV-infected children receiving HAART and is related to the decreased bone mass observed in these children. We also hypothesize that supplementation with vitamin D and the recommended daily allowance of calcium will improve bone mineral accrual in these patients, as it does in healthy individuals. We will test these hypotheses in 1. a crosssectional study comparing HIV-infected and healthy children and adolescents with respect to relationships between HIV-infection, vitamin D status, and bone mass, and in 2. a two-year randomized, controlled clinical trial in which the effects of vitamin D and calcium supplementation on bone mass accrual are compared to placebo in HIV-infected children and adolescents.

描述（由申请人提供）：我们最近观察到，生活在美国东北部城市环境中的HIV感染儿童与健康儿童相比骨量减少。由于儿童期和青春期是骨骼发育的关键时期，而且人们普遍认为，儿童期和青春期的最佳骨量增长可能会预防以后的骨质疏松症，因此这一观察结果对艾滋病毒感染儿童未来发生骨质疏松症和骨折的风险具有严重影响。尽管高效抗逆转录病毒治疗（HAART）与成人骨骼脱矿的病因有关，但对骨骼健康重要的其他因素（如维生素D缺乏）仍可能导致或加剧HIV感染儿童的骨质流失。在这方面，我们发现，50%的一小群艾滋病毒感染儿童体内维生素D储存不足或不足，血清25-羟基维生素D水平低于20 ng/ml。该建议的核心假设是，接受HAART治疗的HIV感染儿童中维生素D缺乏和不足的患病率增加，并与这些儿童中观察到的骨量减少有关。我们还假设补充维生素D和推荐的每日钙摄入量将改善这些患者的骨矿物质积累，就像在健康个体中一样。我们将在1中测试这些假设。一项横断面研究，比较HIV感染和健康儿童和青少年之间的关系，HIV感染，维生素D的状态，和骨量，在2。一项为期两年的随机对照临床试验，在HIV感染的儿童和青少年中，将维生素D和钙补充剂对骨量增加的影响与安慰剂进行比较。